Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The latest breakthroughs at Day One Biopharmaceuticals—from OJEMDA trial readouts to PTK7 ADC progress—are often hidden inside dense SEC prose. Those pages hold the cash-runway figures and regulatory milestones that can shift DAWN’s valuation overnight. If you have ever searched for “Day One Biopharmaceuticals insider trading Form 4 transactions” or wondered how an FDA feedback letter surfaces in an 8-K, you know the challenge of decoding these documents.
Stock Titan’s AI turns that challenge into clarity. Our platform delivers each Day One Biopharmaceuticals annual report 10-K simplified, pulls the numbers you need from every Day One Biopharmaceuticals quarterly earnings report 10-Q filing, and streams Form 4 insider transactions real-time. Interactive summaries translate oncology jargon into plain English so you’re understanding Day One Biopharmaceuticals SEC documents with AI, not sifting through footnotes. Track pipeline spend, compare segments, and see 8-K material events explained the moment they hit EDGAR.
Because Day One’s future rides on pediatric low-grade glioma data and milestone payments, we link each disclosure to what matters: development timelines in MD&A, cash tables for burn-rate analysis, and the Day One Biopharmaceuticals proxy statement executive compensation that aligns leadership incentives. Need a Day One Biopharmaceuticals earnings report filing analysis before the next capital raise? Want alerts on Day One Biopharmaceuticals executive stock transactions Form 4? It’s all here, continuously updated. In short, Day One Biopharmaceuticals SEC filings explained simply—including every Day One Biopharmaceuticals 8-K material events explained and more—so you can act with confidence.
Charles N. York II, COO and CFO of Day One Biopharmaceuticals, Inc. (DAWN), reported settlement and sales related to Restricted Stock Units (RSUs). On 08/15/2025 Mr. York was deemed to have acquired RSUs totaling 16,875 units in four separate grants (1,375; 2,250; 6,625; 6,625). These RSUs convert one-for-one into common shares upon settlement for no consideration and vest in quarterly 1/16th installments on Feb 15, May 15, Aug 15 and Nov 15, subject to continued service. Following those acquisitions his reported beneficial ownership increased through successive totals shown up to 282,106 shares.
On 08/18/2025 Mr. York sold 4,106 shares at a weighted average price of $6.7671 as part of block trades executed at prices ranging from $6.65 to $6.87; the sale was made solely to cover tax withholding for the RSU settlements. The filing is signed and dated 08/19/2025 and discloses no other transactions or amendments.
Day One Biopharmaceuticals insider transactions: Adam Dubow, listed as the issuer's General Counsel & Secretary and an officer, had multiple Restricted Stock Units (RSUs) settle on 08/15/2025, resulting in the acquisition of 11,087 shares of common stock through four RSU settlements and increasing his reported beneficial ownership in steps to 59,223 shares before a subsequent sale. On 08/18/2025 Dubow sold 4,365 shares in a block trade at a weighted average price of $6.7671 per share; the filing states the sale was made solely to cover tax liabilities related to the RSU settlements. The filing discloses vesting schedules for the RSUs (initial 25% vesting on 11/15/2023, then quarterly installments or 1/16th per quarter as specified) and confirms RSUs convert to one share each upon settlement for no consideration.
Jeremy Bender, Chief Executive Officer and director of Day One Biopharmaceuticals, Inc. (DAWN), reported vesting settlements of multiple Restricted Stock Units (RSUs) on 08/15/2025 that converted into common shares and a subsequent sale on 08/18/2025. The Form 4 shows acquisitions by settlement: 3,562, 4,750, 11,687 and 11,687 RSUs converting to common stock. On 08/18/2025 the filing reports a sale of 16,058 shares at a weighted average price of $6.7671, disclosed as executed to cover the reporting person's tax liability from RSU settlement. The filing also discloses significant indirect holdings across several trusts, including 1,408,285 shares held in the Bender Revocable Trust.
Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, Inc. (DAWN), reported receipt and partial sale of company shares tied to vested restricted stock units (RSUs). On 08/15/2025 she was treated as acquiring multiple blocks of common stock through vesting of RSUs (3,162; 3,687; 3,687 shares) and the related derivative entries show those RSUs underlie the same share amounts. Following these transactions her reported beneficial ownership figures adjusted across several lines, and on 08/18/2025 she sold 3,766 shares in a block trade at a weighted average price of $6.7671 to cover taxes on RSU settlement.
The filing notes the RSUs represent one share each upon settlement for no consideration, vesting schedules (initial 1/4 on 08/15/2024 with remaining quarterly vesting, and separate 1/16 quarterly vesting for another award) and that RSU sales were solely to cover tax liabilities. The form was filed by one reporting person via attorney-in-fact.
Day One Biopharmaceuticals (DAWN) filed a Form 144 reporting a proposed sale of 16,058 common shares acquired as restricted stock from the issuer on 08/15/2025. The sale is to be effected through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value reported as $108,666.09 and the issuer's total shares outstanding listed as 102,431,933.
The notice records the approximate sale date as 08/18/2025, states no securities were sold by the reporting person in the past three months, and includes the standard representation that the seller is not aware of undisclosed material adverse information. Payment and acquisition details show the shares were issued and paid on 08/15/2025 and described as not applicable for other payment types.
Day One Biopharmaceuticals, Inc. (DAWN) Schedule 13G/A reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals, Peter Kolchinsky and Rajeev Shah, each disclose 0.00 shares beneficially owned as of June 30, 2025, representing 0.0% of the company’s common stock. The filing lists the reporting persons' citizenships and principal business address and confirms the reporting status and classifications (IA, PN, HC, IN). The report includes a certification that the securities were not acquired to influence control. A Joint Filing Agreement is incorporated by reference.
FAQ
What is the current stock price of Day One Biopharmaceuticals (DAWN)?
What is the market cap of Day One Biopharmaceuticals (DAWN)?
